SynthesisThe Canadian journal of cardiology2023
One-Year Risk of Myocarditis After COVID-19 Infection: A Systematic Review and Meta-analysis.
Synthesis in The Canadian journal of cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 32 citations in OpenAlex.
- Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies.Human vaccines & immunotherapeutics · 2026Review
- Global epidemiology of myocarditis: disparities in age, sex and geography.Nature reviews. Cardiology · 2026Review
- Pre-existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18-30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data.Drugs - real world outcomes · 2026Article
- Deep learning-driven 3-D histopathology method: a pipeline for cellular-resolution myocarditis analysis.American journal of physiology. Heart and circulatory physiology · 2026Article
- The Impact of COVID-19 Infection and Vaccination on Myocarditis Incidence: A Comparative Analysis of Pre-, Peri-, and Post-Pandemic Eras.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- Echocardiogram Testing in Patients with Post-COVID-19 Condition: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Post-infection sequelae of COVID-19 and other infectious diseases-a nationwide Danish study with 40-month follow-up.Nature communications · 2026Article
- Scientific communication and vaccine hesitation: an analysis of the editorial line of a great Brazilian newspaper.Oxford open immunology · 2026Article
- Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19.Infection & chemotherapy · 2025Review
- Review
- Inflammasomes as Potential Therapeutic Targets to Prevent Chronic Active Viral Myocarditis-Translating Basic Science into Clinical Practice.International journal of molecular sciences · 2025Review
- Non-Ischemic Pattern of LGE After COVID-19 Correlates More with Severity of Acute Illness than with Long-Term Myocardial Dysfunction.Journal of clinical medicine · 2025Article
- Do Long COVID and COVID Vaccine Side Effects Share Pathophysiological Picture and Biochemical Pathways?International journal of molecular sciences · 2025Review
- COVID-19 and Myocarditis: Trends, Clinical Characteristics, and Future Directions.Journal of clinical medicine · 2025Review
- Myocardial Fibrosis in a Recovered COVID-19 Patient: A Case Indicating Prior Myocarditis.Cureus · 2025Article
- Global, regional, and national burden of elderly myocarditis (1992-2021) and projections of future disease burden trends.Aging clinical and experimental research · 2025Article
- Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands.Advances in therapy · 2025Article
- Article
- Myocarditis after COVID-19 and influenza infections: insights from a large data set.Open heart · 2024Article
- Clinical Presentation and Outcomes of Myocarditis Among the COVID-19 Pediatric Population: A Review of 100 Cases.Cureus · 2024Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myocarditis has been described as a relatively rare cardiovascular complication of COVID-19 infection. However, data regarding the risk of myocarditis during the post-acute phase of COVID-19 are scant. We assess the risk of incident myocarditis in COVID-19 survivors within 1 year from the index infection by a systematic review and meta-analysis of the available data.
methodsData were obtained by searching Medline and Scopus for all studies published at any time up to September 1, 2022, and reporting the long-term risk of incident myocarditis in COVID-19 survivors. Myocarditis risk data were pooled using the Mantel-Haenszel random-effects models with hazard ratio (HR) as the effect measure with 95% confidence interval (CI). Heterogeneity among studies was assessed using the Higgins-Thompson I
resultsOverall, 20,875,843 patients (mean age 56.1 years, 59.1% male) were included in this analysis. Of them, 1,245,167 experienced (and survived) COVID-19 infection. Over a mean follow-up of 9.5 months, myocarditis occurred to 0.21 (95% CI 0.13-0.42) out of 1000 patients survived to COVID-19 infection compared with 0.09 [95% CI 0.07-0.12) out of 1000 control subjects. Pooled analysis revealed that recovered COVID-19 patients presented an increased risk of incident myocarditis (HR 5.16, 95% CI 3.87-6.89; P < 0.0001; I
conclusionsOur findings suggest that myocarditis represents a relatively rare but important post-acute COVID-19 sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.